Cytelabs Introduces Rapid DISH Testing for Breast Cancer Diagnosis

The move positions Cytelabs as the first standalone private laboratory in India to offer this FDA-approved technique, streamlining HER2 testing for precision therapy in breast cancer.

Cytelabs, a leading oncopathology diagnostic service affiliated with Cytecare Cancer Hospital, has unveiled Dual in situ hybridisation (DISH) testing for breast cancer, marking a significant leap in diagnostic efficiency. 

The move positions Cytelabs as the first standalone private laboratory in India to offer this FDA-approved technique, streamlining HER2 testing for precision therapy in breast cancer.

Commenting on the  importance of accessible technology in India, Dr Aparna Gangoli, director at Cytelabs, said, "DISH promises quality results and short turnaround time, ensuring that the treatment for breast cancer can be planned and initiated without wasting undue time."

HER2 testing is pivotal in categorising breast cancer cases into HER2-positive and HER2-negative groups. For HER2-positive patients, targeted therapy with Trastuzumab can be beneficial. Traditionally, Fluorescent in situ hybridization (FISH) has been the go-to technique for HER2 status determination, requiring outsourcing and leading to a lengthy waiting period.

DISH, however, delivers the final HER2 status report within 24-48 hours, a game-changer in diagnostic timelines. Dr. Gangoli explained, "Unlike FISH, DISH is interpreted through the usual binocular, non-fluorescent microscope, providing a quicker and equally effective alternative."

The efficiency of DISH lies in its interpretation through the Ventana automated platform, offering accessible and affordable services. Currently available across 65 partner hospitals in Karnataka, Andhra Pradesh, and Telangana, Cytelabs aims to facilitate seamless and timely treatment decisions for oncologists and patients.

Launched in 2020 by Cytecare Cancer Hospital, Cytelabs provides easy access to high-quality cancer diagnostic services to surgeons and patients across 65 partnered hospitals in Karnataka, Andhra Pradesh, and Telangana. 

Cytelabs utilises advanced technologies and techniques to conduct oncopathological testing. The lab also performs specialised tests, such as immunohistochemistry (IHC), integral to cancer diagnosis, using the automated Ventana platform for diagnostic and prognostic purposes. 

Additionally, the doctors from Cytelabs conduct annual DIY IHC workshops for medical students and budding pathologists to help spread awareness and knowledge.

In related developments, GE HealthCare launched MyBreastAI Suite to address the global rise in cancer cases. This platform integrates AI applications, including ProFound AI for DBT, SecondLook for 2D Mammography, and PowerLook Density Assessment, promising early detection and improved patient outcomes.

Likewise, in November, FUJIFILM India launched a nationwide breast cancer screening campaign, reinforcing the commitment to early detection and accessible healthcare for women across the country.